5-Ethyl-7,8-dimethoxy-pyrrolo[3,4-c]isoquinoline-1,3-dione | 159109-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-Ethyl-7,8-dimethoxy-pyrrolo[3,4-c]isoquinoline-1,3-dione
• 英文别名: 5-ethyl-7,8-dimethoxypyrrolo[3,4-c]isoquinoline-1,3-dione
• CAS: 159109-11-2
• 化学式: C₁₅H₁₄N₂O₄
• 分子量: 286.28
• InChiKey: ULVWJFBHQIXEPE-UHFFFAOYSA-N

物化性质

• 密度：
  1.327±0.06 g/cm3(Predicted)
• 溶解度：
  在 DMSO 中溶解度为 25 mM

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Peritoneal dialysis fluid comprising a GSK-3 inhibitor
  申请人：Zytoprotec GmbH

  公开号：EP2609918A1

  公开（公告）日：2013-07-03

  The present invention relates to a peritoneal dialysis fluid comprising a compound inhibiting glycogen synthase kinase (GSK)-3 activity, in particular (GSK)-3β activity, for use in the prevention of infectious and non-infectious peritoneal complications such as peritonitis, peritoneal membrane injury, damage and failure, barrier dysfunction and mesothelial cell detachment.

  本发明涉及一种腹膜透析液，其中含有一种抑制糖原合酶激酶（GSK）-3 活性，特别是抑制（GSK）-3β 活性的化合物，用于预防感染性和非感染性腹膜并发症，如腹膜炎、腹膜损伤、破坏和失效、屏障功能障碍和间皮细胞脱落。
• METHOD OF TREATMENT OF PARKINSONISM
  申请人：Fundacio Centre de Regulacio Genomica

  公开号：EP3231434A1

  公开（公告）日：2017-10-18

  The invention relates to a cell selected from the group consisting of a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), and a mesenchymal stem cell (MSC), or a cell population comprising any combination thereof, for use in the treatment of Parkinsonism in a subject, and to pharmaceutical compositions and kits for use in the treatment of Parkinsonism.

  本发明涉及一种选自造血干细胞（HSC）、造血祖细胞（HPC）和间充质干细胞（MSC）组成的组的细胞，或由其任意组合而成的细胞群，用于治疗受试者的帕金森病，还涉及用于治疗帕金森病的药物组合物和试剂盒。
• METHOD FOR GENERATING FUNCTIONAL SKELETAL MUSCLE FIBERS INNERVATED BY MOTONEURONS
  申请人：Association Française contre les Myopathies (AFM)

  公开号：EP3913047A1

  公开（公告）日：2021-11-24

  The present invention relates to a method for the generation of functional skeletal muscle fibers innervated by motoneurons, from pluripotent stem cells.

  本发明涉及一种利用多能干细胞生成由运动神经元支配的功能性骨骼肌纤维的方法。
• Maturation of hepatocyte-like cells derived from human pluripotent stem cells
  申请人：Takara Bio Europe AB

  公开号：US10294457B2

  公开（公告）日：2019-05-21

  The present invention relates to directed differentiation and maturation of hepatocyte-like cells. In particular, the present invention relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of GSK-3 (Glycogen synthase kinase 3) or activator of Wnt signalling and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The present invention also relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of a cycline dependent kinase (CDK) and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The hepatocyte-like cells obtained in accordance with the present invention show a phenotype which is more similar to that of primary hepatocytes than previously shown.

  本发明涉及肝细胞样细胞的定向分化和成熟。特别是，本发明涉及将肝细胞样细胞暴露于视黄酸反应受体的激活剂，如视黄酸（RA），可选择与 GSK-3（糖原合酶激酶 3）抑制剂或 Wnt 信号激活剂结合使用，和/或将细胞与哺乳动物细胞外基质的一种或多种特征成分（基质覆盖）结合使用。本发明还涉及将肝细胞样细胞暴露于视黄酸反应受体的激活剂，如视黄酸（RA），可选择与细胞周期依赖性激酶（CDK）抑制剂结合使用，和/或将细胞与哺乳动物细胞外基质的一种或多种特征成分覆盖（基质覆盖）。根据本发明获得的肝细胞样细胞显示出的表型比以前显示的更类似于原代肝细胞的表型。
• Differentiation of hepatocyte-like cells from stem cells
  申请人：Agency for Science, Technology and Research

  公开号：US10323228B2

  公开（公告）日：2019-06-18

  Disclosed are methods of differentiating stem cells in order to obtain hepatocyte-like cells, the method comprising the steps of a) subjecting definitive endoderm to at least one epigenetic modulator to obtain hepatoblasts and b) subjecting the hepatoblasts to at least one stem cell differentiation pathway inhibitor to obtain hepatocyte-like cells; wherein steps a) and b) do not comprise the use of a growth factor. In one preferred embodiment, the epigenetic modulator may be sodium butyrate and/or DMSO and the stem cell differentiation pathway inhibitor may be SB431542 and/or DMSO. Also disclosed are hepatocyte-like cells obtained from the method and uses of these cells such as drug screening.

  本发明公开了分化干细胞以获得肝细胞样细胞的方法，该方法包括以下步骤：a)将确定的内胚层置于至少一种表观遗传调节剂中以获得肝母细胞；b)将肝母细胞置于至少一种干细胞分化途径抑制剂中以获得肝细胞样细胞；其中步骤a)和b)不包括使用生长因子。在一个优选的实施方案中，表观遗传调节剂可以是丁酸钠和/或二甲基亚砜，干细胞分化途径抑制剂可以是SB431542和/或二甲基亚砜。还公开了从该方法中获得的肝细胞样细胞以及这些细胞的用途，如药物筛选。